| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.095 | 0.1 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.28 | 0.1 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.074 | 0.1 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |